Please Wait

Applying Filters...

C14H21N3O2S
KDMF
Table View

Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

C14H21N3O2S

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

57 API Suppliers, 26 USDMF, 15 CEP/COS, 4 JDMF, 14 EU WC, 6 KDMF, 17 NDC API, 24 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

33 Drugs in Development

33 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

462 FDF Dossiers, 105 FDA Orange Book, 277 Europe, 33 Canada, 13 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma, 1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

3 Parenteral, 1 Topical

DIGITAL CONTENT

36 News #PharmaBuzz

36 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions, 154 Regulatory FDF Prices, 8 Annual Reports

MARKET PLACE

13 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 6 Others

$ Xls download

Filters

Log in to download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Divis Laboratories	India	GlaxoSmithKline Inc.	20211115-209-J-1150	sumatriptan succinate	2021-11-15	Divi's Laboratories Limited	India	Unit-2, Annavaram (Post), Chippada Village, Bheemunipatnam Mandal, Visakhapatnam District –531 162, Andhra Pradesh, India
29/11/2025	HUNAN JIUDIAN PHARMACEUTICAL CO LTD	China	Lihu Healthcare Co., Ltd.	20251113-209-J-2054	sumatriptan succinate	2025-11-13	Hunan Jiudian Hongyang Pharmaceutical. Co., Ltd.	China	Tongguan Circular Economy Industrial Base, Wangcheng Economic and Technological Development Zone, Hunan, China

Contact us
to update this info

C14H21N3O2S

C14H21N3O2S

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

57 API Suppliers

26 USDMF

15 CEP/COS

4 JDMF

14 EU WC

6 KDMF

17 NDC API

24 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

33 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

462 FDF Dossiers

105 FDA Orange Book

277 Europe

33 Canada

13 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

2 Kirsch Pharma

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

3 Parenteral

1 Topical

DIGITAL CONTENT

36 News #PharmaBuzz

GLOBAL SALES INFORMATION

31 US Medicaid Prescriptions

154 Regulatory FDF Prices

8 Annual Reports

MARKET PLACE

13 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

49 US Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

6 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons